Immunotherapy is a groundbreaking cancer treatment being offered by the experts at Moffitt Cancer Center. As pioneers of this promising option, we believe it has unprecedented potential to make a difference in the lives of many current and future cancer patients. By capitalizing on the natural power of the body’s immune system, novel immunotherapy treatments can help defend a patient’s body against the growth and spread of cancerous cells.
At Moffitt, patients can access numerous different immunotherapy treatments through select FDA-approved therapies, as well as our clinical trials program. As a National Cancer Institute-designated Comprehensive Cancer Center, we have a robust research program and are able to match patients with a variety of cancers with clinical trials that meet their unique needs. Physicians may refer their patients to Moffitt to access a variety of immunotherapy treatments, including:
- Cancer vaccines
- Monoclonal antibodies
- Immune checkpoint inhibitors
- Cellular immunotherapy, also called adoptive cell therapy, including:
- Chimeric antigen receptor (CAR) T cell therapy
- Tumor-infiltrating lymphocyte (TIL) therapy
- T-cell receptor (TCR) therapy
To rapidly and safely bring pivotal trials to cancer patients and to prepare for additional cell therapy trials in solid and liquid tumors from both industry and our own investigators, Moffitt utilizes a collaborative cross departmental program to provide clinical care and trial coordination for immune cell therapies. The Moffitt Immune Cell Therapy (ICE-T) service oversees and administers CAR-T cell therapy for hematologic malignancies, along with TIL and TCR therapy for solid tumor patients. Disease specific experts maintain oversight as principal investigators of these key trials yet the coordination and clinical care is centralized to leverage the expertise and infrastructure of our already robust program.
We conduct immunotherapy trials for patients with a variety of advanced-stage, solid and liquid tumors, including:
- Brain cancers
- Lung cancer
- Multiple myeloma
- Ovarian cancer
- Cervical cancer
- Breast cancer
- Head and neck cancers
- Gastrointestinal cancers
Immune-based therapies hold exceptional promise. Therefore many of our trials are open to patients who have already completed one or more other treatments without obtaining the desired outcomes. To ensure that each patient receives the treatment that is most likely to benefit his or her unique situation, we conduct a comprehensive series of evaluations prior to enrolling a patient in a trial.
Because of the risk of cytokine release syndrome (CRS) and adverse neurological events, the FDA is requiring that hospitals and their associated clinics that dispense CAR-T cell therapy be specially certified. At Moffitt Cancer Center, staff involved in the prescribing, dispensing, or administering of cell therapies are required to be trained to recognize and manage CRS and neurological events.
The multispecialty experts at Moffitt are committed to providing outstanding clinical care for patients who are receiving immunotherapies. As part of this process, we continually review each patient’s response to treatment and revise his or her treatment plan as necessary. The leadership at Moffitt is also continually recruiting outstanding new faculty members to further develop our immunotherapy offerings.